Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Warfarin placebo Clear all
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

NCT00786474
View directory record Official record
Conditions
Arterial Thromboembolic Events, Atrial Fibrillation
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Cytochrome P450 4F Enzymes and Drug Interactions

NCT01250535
View directory record Official record
Conditions
Healthy Volunteers, Drug Drug Interactions
Interventions
Warfarin, Placebo, Lovastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, warfarin plus ABT-335 plus rosuvastatin 5 mg, warfarin plus ABT-335 plus rosuvastatin 20 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 2 Interventional Results available

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 4, 2026, 9:24 PM EDT
Terminated Phase 3 Interventional Results available

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

NCT00957242
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
warfarin, placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Warfarin Versus Aspirin Recurrent Stroke Study

NCT00027066
View directory record Official record
Conditions
Stroke
Interventions
Active Aspirin, Active Warfarin, Aspirin placebo, Warfarin placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
2,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 4, 2026, 9:24 PM EDT
Recruiting Early Phase 1 Interventional

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
Behavioral · Drug · Procedure
Lead sponsor
China National Center for Cardiovascular Diseases
Government
Eligibility
18 Years and older
Enrollment
3,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional

Patent Foramen Ovale in Cryptogenic Stroke Study

NCT00697151
View directory record Official record
Conditions
Ischemic Stroke, Patent Foramen Ovale
Interventions
Warfarin, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional

Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

NCT00345618
View directory record Official record
Conditions
Embolism, Thrombosis
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 4, 2026, 9:24 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 4, 2026, 9:24 PM EDT